CHMP positive opinion recommending approval of Benlysta for adult patients with active lupus nephritis
The Pharma Data
MARCH 26, 2021
The CHMP opinion is one of the final steps in the marketing authorisation procedure prior to approval by the European Commission. The CHMP’s positive opinion brings us one step closer to providing physicians and patients in Europe with the first treatment option specifically designed to work in lupus and lupus nephritis.”.
Let's personalize your content